Listen

Press releases

Receive e-mail alerts

Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
January 07, 2021 at 12:00 PM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index
December 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10
December 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
December 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires
December 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10
December 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
December 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference
November 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018
November 07, 2018 at 12:00 PM UTC
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
October 31, 2018 at 11:00 AM UTC
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals
October 30, 2018 at 10:15 PM UTC
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
October 29, 2018 at 11:33 AM UTC
Internal link ProQR to Present at the Chardan Genetic Medicines Conference
October 02, 2018 at 11:00 AM UTC
Internal link ProQR Announces Presentations at the OTS Annual Meeting
September 24, 2018 at 11:00 AM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 11, 2018 at 08:01 PM UTC
Internal link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
September 07, 2018 at 08:21 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
September 05, 2018 at 08:01 PM UTC
Internal link ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3
September 05, 2018 at 09:46 AM UTC
Internal link ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
September 05, 2018 at 08:00 AM UTC
Internal link ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
August 15, 2018 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the Second Quarter of 2018
August 08, 2018 at 11:00 AM UTC
Internal link ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids
August 01, 2018 at 11:00 AM UTC
Internal link ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July
July 12, 2018 at 11:00 AM UTC
Internal link ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
June 28, 2018 at 11:00 AM UTC
Internal link ProQR to Present at the JMP Life Sciences Conference
June 14, 2018 at 11:00 AM UTC

Press releases

Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10

Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index

Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10

Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires

Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients

Internal link ProQR to Present at the Evercore ISI HealthConX Conference

Internal link ProQR Announces Financial Results for the Third Quarter of 2018

Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference

Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals

Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

Internal link ProQR to Present at the Chardan Genetic Medicines Conference

Internal link ProQR Announces Presentations at the OTS Annual Meeting

Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Internal link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares

Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Internal link ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3

Internal link ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

Internal link ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

Internal link ProQR Announces Financial Results for the Second Quarter of 2018

Internal link ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

Internal link ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

Internal link ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

Internal link ProQR to Present at the JMP Life Sciences Conference